[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:antinuclear-antibody":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Antinuclear Antibody",27,24,[8,16,23,29,36,42,49,56,62,67,73,79,86,92,98,104,110,116,122,128,134,140,146,152,158,165,172],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06570798","A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases",[12],"Phase 2","RECRUITING","2026-08-26T02:15:10.362237Z","2026-07-24T01:27:14.890537Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06934915","Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder",[20],"Early Phase 1","2026-08-26T02:18:34.622081Z","2026-07-19T19:36:05.058787Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07053800","Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)",[12],"2026-08-26T02:15:42.447052Z","2026-07-05T05:32:16.729991Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07201558","Study Evaluating Safety, Tolerability, PK\u002FPD of Surovatamig in Adult RA or SLE Participants",[33],"Phase 1","2026-08-26T02:17:36.611194Z","2026-07-05T05:32:16.666464Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05268289","Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +\u002F- V",[12],"2026-08-26T02:18:22.309547Z","2026-05-29T15:36:40.174644Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT07430306","A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus",[46],"Phase 3","2026-08-26T02:17:06.985283Z","2026-05-13T02:55:06.705839Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":54,"content_modified":55},"NCT06897930","A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE",[53],"Phase 1\u002FPhase 2","2026-08-26T02:16:35.654046Z","2026-05-05T02:43:28.793672Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06655155","A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.741208Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":14,"content_modified":66},"NCT06581198","A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE\u002FLN)",[12],"2026-05-05T02:43:28.728724Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06470048","A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis",[12],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.675620Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07219563","Alnuctamab for Refractory SLE (LATTE Study)",[33],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.475692Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT07225387","Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial",[83],"Phase 4","2026-08-26T02:15:58.452248Z","2026-05-05T02:43:27.813070Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT06625671","A Phase 1\u002F2a Study of DB-2304 in Healthy Adults and SLE Participants",[53],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.671925Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06737380","UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients",[33],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.646843Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06613360","A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus",[33],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.314554Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07260877","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus",[12],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.251049Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06977724","A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)",[33],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:26.921745Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT07409181","A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:35:31.877860Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06839976","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus",[53],"2026-08-26T02:17:20.511551Z","2026-05-05T02:35:31.669019Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06916806","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.",[33],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.362747Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[53],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.675534Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07175285","A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants",[],"2026-08-26T02:17:48.768272Z","2026-05-13T02:55:06.670897Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT02234388","Undifferentiated Connective Tissue Disease Registry",[],"2026-08-26T02:19:02.550788Z","2026-05-13T02:55:06.091190Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT07607964","A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)",[33],"2026-08-26T02:17:42.501124Z","2026-05-29T15:36:40.226566Z",{"nct_id":159,"title":160,"phases":161,"status":162,"updated_at":163,"content_modified":164},"NCT07335562","A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel \u002F Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis",[46],"NOT_YET_RECRUITING","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:26.746670Z",{"nct_id":166,"title":167,"phases":168,"status":169,"updated_at":170,"content_modified":171},"NCT06518668","A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus",[33],"ENROLLING_BY_INVITATION","2026-08-26T02:16:04.914942Z","2026-07-05T03:45:20.249630Z",{"nct_id":173,"title":174,"phases":175,"status":176,"updated_at":177,"content_modified":178},"NCT05648500","A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus",[46],"ACTIVE_NOT_RECRUITING","2026-08-03T02:17:17.775722Z","2026-05-05T02:43:28.643616Z"]